1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Lipocine Inc.
  6. News
  7. Summary
    LPCN   US53630X1046

LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)

12/22/2021 | 11:24am EDT

Item 8.01 Other Events

On December 22, 2021, the Company issued a press release announcing that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) with LPCN 1148 for the management of liver cirrhosis. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d)    Exhibits


The following exhibits are filed with this report:



Exhibit No.   Description

99.1            Press Release announcing Patient Dosed in Phase 2 Study with LPCN
              1148 for the Management of Liver Cirrhosis

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12LIPOCINE INC. : Financial Statements and Exhibits (form 8-K)
AQ
05/12LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/09LIPOCINE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
More news
Analyst Recommendations on LIPOCINE INC.
More recommendations
Financials (USD)
Sales 2022 2,21 M - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,00x
Yield 2022 -
Capitalization 76,1 M 76,1 M -
Capi. / Sales 2022 34,5x
Capi. / Sales 2023 10,2x
Nbr of Employees 13
Free-Float 97,5%
Chart LIPOCINE INC.
Duration : Period :
Lipocine Inc. Technical Analysis Chart | LPCN | US53630X1046 | MarketScreener
Technical analysis trends LIPOCINE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,86 $
Average target price 3,67 $
Spread / Average Target 326%
EPS Revisions
Managers and Directors
Mahesh V. Patel Chairman, President, Chief Executive Officer & CFO
Anthony DelConte Chief Medical Director
Richard Dana Ono Independent Director
Jeffrey Arvin Fink Independent Director
Jill M. Jene Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIPOCINE INC.-13.22%76
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958